* If you want to update the article please login/register
Introduction: Inflammatory Bowel Disease is a disease of intestinal inflammation, characterized by intestinal inflammation and classified into Crohn's Disease and Ulcerative Retrocolitis. There are a number of studies that show the beneficial and potential effects of phytocannabinoids on Inflammatory Bowel Disease. Objective: A systematic review study was conducted to determine the beneficial effects of Cannabis sativa-derived metabolites in the treatment of IBD, which was closely linked to the use of nanotechnology in order to increase this result. Methodology: In the following databases: PUBMED, Science Direct, and Scopus, this systematic review of the literature of pre-clinical and clinical trials was published: From 2012 to 2022. In Pubmed, 80 articles in Science Direct and 443 in Scopus, a total of 418 articles were found. Conclusion: Considering all of the above, it can be inferred that metabolites derived from Cannabis sativa have a lot of promise in the treatment of inflammatory bowel diseases.
Source link: https://doi.org/10.33448/rsd-v11i10.33011
Background: The TRANS-IBD report investigates the effectiveness of joint transition visits, as well as medication compliance and patient satisfaction as among the outcome outcomes. Patients with inflammatory bowel disease questionnaires [u2019] and u2018Patient satisfaction with health care in inflammatory bowel disease questionnaires showed an inter-cultural, age- and disease-specific modification of the u2018Medication Adherence Rating Scale. The CAHCE questionnaire had poor fit values in the MARS questionnaire and good fit values, according to CFI and TLI's statistically acceptable findings. Conclusion: The questionnaires were produced in Hungary, which are suitable tools for TRANS-IBD RCT and daily IBD care.
Source link: https://doi.org/10.3390/children9081143
The central nervous system has extensive innervation, including the gastrointestinal tract, which allows the possibility of using nerve stimulation to treat gastrointestinal disorders such as Inflammatory Bowel Disease. This review was designed to publish a bibliographic review of the primary clinical studies that connect IBD therapy with neural electrical stimulation. 'electrical stimulation," "electric neuromodulation," "inflammatory bowel disease," "ulcerative colitis," and "Crohn's Disease" were among the search terms used for the search. The nerves modulate inflammation in the gut, but the clinical protocols for anti-inflammatory agents have had uneven success, though.
Source link: https://doi.org/10.34117/bjdv8n8-038
History: Ulcerative colitis and Crohn's disease are two examples of inflammatory bowel disease. Methods: The disease activity was measured by clinical activity indices, as shown by clinical activity indices. Bowel wall thickness, loss of bowel stratification, loss of haustration, and the presence of increased lymph nodes, mesenteric masses, absces, fistula, and quantitative vascular signal patterns of the bowel were investigated in conjunction with u201chypo and hyperflow, as u201d and hyper-flow values were investigated. In comparison to BWT and clinical use, Vascular signal patterns and the CQ values have risen and decreased. IBD patients were screened for fifty-two patients. Patients with elevated BWT at the transverse colon had an increased incidence of the u201chyper-flow pattern. At the caecum, transverse colony, and descending colon, there was a positive correlation between the CQ values and BWT. Conclusion: Visual vascular signal scores and CQ results that have been raised may be useful in detecting IBD-related disease activity in patients with IBD.
Source link: https://doi.org/10.2174/0929867328666201228124621
In up to 30% of patients being monitored for inflammatory bowel disease, inflammatory bowel disease has been identified. Erosive arthritic disease related to inflammatory bowel disease is less common, but it does cause ligamentous laxity and joint instability. A 56-year-old woman with a long history of ulcerative colitis, presented with atlantoaxial dysfunction and underwent a C1-3 fusion; however, significant occipitoatlantal turmoil was not apparent. The patient's neurological abnormality was completely addressed postoperatively, according to the patient.
Source link: https://doi.org/10.3171/foc.19188.8.131.52
BACKGROUND: Immunosuppressive drugs used in the treatment of inflammatory bowel diseases may potentially raise the risk of coronavirus disease in 2019. We wanted to compare COVID-19 prevalence in patients with IBD with their families and determine the causal risk factors. METHODS: Firstly, a multi-center, observational research of 2110 patients with IBD and 2110 age-matched household members was conducted to determine COVID-19 frequency. Secondly, the records of patients with IBD and COVID-19 who had called the COVID-19 hotline were included. RESULTS: The prevalence of COVID-19 in patients with IBD and household groups was similar. Among those with three or more comorbidities, the incidence of COVID-19 increased from 1. 9 percent to 7. 1%, but it was significantly higher in those with severe IBD. CONCLUSION: The prevalence of COVID-19 in patients with IBD was similar to that of household members. Only patients with IBD who are receiving anti-TNF monotherapy had a higher risk of COVID-19 susceptibility.
Source link: https://doi.org/10.34172/mejdd.2022.271
BACKGROUND: Coronavirus disease 2019 caused a global pandemic. Both Crohn's disease and ulcerative colitis are two forms of inflammatory bowel disease. IBD is a common inflammatory disease with a high global prevalence. Concerns about the exacerbation of COVID clinical manifestations in patients with IBD and raising the risk of mortality have been raised. In this report, we investigated unique questions regarding IBD risk in the population, as well as disease control, and vaccination rates during the COVID-19 pandemic.
Source link: https://doi.org/10.34172/mejdd.2022.269
BACKGROUND: Patients' decision aid is a device that supports shared decisionmaking enhancements and is a component of the change from physician-centered decision making to patient-centered decision making. We wanted to explore the process used to create a PDA for facilitating shared decision-making regarding treatment of patients with inflammatory bowel disease who need medications or surgery in this review. PDA's final PDA contains four key parts: a: Introduction to IBD disease, the purpose of creating PDA, and an emphasis on shared decision-making 2 Benefits and risks of key drugs 3 The conclusion about patients' satisfaction with PDA is used to determine the treatment options.
Source link: https://doi.org/10.34172/mejdd.2022.256
Knowing the risk factors that can be modified could reduce the cost burden on patients with inflammatory bowel disease and the health system. Both robust logistic regression and multinomial logistic regression were used to determine the variables associated with binary and categorical dependent variables. RESULTS: 187 patients were admitted during a four-year study period for an IBD-related cause, among whom 131 patients developed ulcerative colitis, and 56 patients had Crohn's disease. Moreover, 29 percent of the participants had been readmitted at least once during the study period, and seven patients with IBD had been readmitted five or more times during the study period. CONCLUSION: According to 30-day readmission, one out of seven hospitalizations of patients with IBD leads to 30-day readmission. Likewise, younger patients with IBD and shorter hospital stays were more likely to be readmitted five or more times during the study period.
Source link: https://doi.org/10.34172/mejdd.2022.253
BACKGROUND: It is vital to concentrate during the coronavirus disease 2019 pandemic to focus on patients with chronic diseases' influence on COVID-19 and its severity. In a cohort of patients with inflammatory bowel disease, this study sought to determine the COVID-19 incidence rate, patients'u2019 questions, sources of evidence, and medication compliance in a cohort of patients with inflammatory bowel disease. The COVID-19 cases had been repeated three months later to assess the post-COVID-19 symptoms and conditions. The meanu00b1SD's scores of commitment to standard preventive instructions on COVID-19 were 81. 6u00b119. In addition, ten patients with IBD were confirmed as confirmed cases of COVID-19, one of whom was dead due to severe acute respiratory syndrome. CONCLUSION: In the cohort of the patients with IBD in this study, the incidence of COVID-19 was broadly similar to the general reference population.
Source link: https://doi.org/10.34172/mejdd.2022.252
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions